LYT-100 | MedDataX

Drug Profile

LYT-100 (deupirfenidone) is a next-generation deuterated form of pirfenidone being developed for idiopathic pulmonary fibrosis and related fibrotic conditions. It has completed Phase 2b and is being advanced toward pivotal Phase 3 development. The program is investigational and not approved by regulatory authorities.

Drug Class: Deuterated antifibrotic small molecule (deuterated pirfenidone)
Approval Status: Investigational drug; not approved by any regulatory authority.
Mechanism of Action: Designed to retain pirfenidone pharmacology while slowing metabolic breakdown via deuteration to improve exposure and tolerability.

Indications

\Idiopathic pulmonary fibrosis (IPF)\
\Other fibrotic diseases in development\

Related News

PureTech's Deupirfenidone Receives FDA and EU Orphan Drug Designation for IPF

Feb 20, 2026

PureTech Health's deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for treating idiopathic pulmonary fibrosis, a rare and fatal lung disease. Phase 2b trial results showed superior efficacy compared to existing therapies.

Three Clinical Trial Pipeline Reports Track Progress in Prostate Cancer, NK Cells, and Lung Diseases

Feb 15, 2026

DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT04652518	LYT-100 in Post-acute COVID-19 Respiratory Disease	TERMINATED	PHASE2